Daytrana Methylphenidate Transdermal Patches Recalled for Defective Delivery System
Noven Pharmaceuticals recalls Daytrana (methylphenidate) 30 mg transdermal patches nationwide due to defective delivery system components that fail shear specifications. Patients should contact their healthcare provider regarding medication alternatives.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall without reported hospitalizations or illnesses. The defective delivery system of a prescription CNS stimulant represents a risk-of-harm scenario with no documented patient harm, meeting the High severity criterion.
Plain-English summary
Noven Pharmaceuticals Inc has issued a nationwide recall of Daytrana (methylphenidate) 30 mg transdermal patches. Multiple manufacturing lots are affected, with expiration dates ranging from March 2023 through October 2023.
The recall was initiated because the delivery system in these patches does not meet specifications for shear. This defect could compromise the patches' ability to adhere properly and deliver the prescribed dose of methylphenidate.
Daytrana is a prescription medication used to treat attention-deficit/hyperactivity disorder (ADHD). Patients currently using affected patches should contact their prescribing healthcare provider to discuss their medication options and obtain alternative treatment if necessary.
The recalled product
- Product
- DAYTRANA (METHYLPHENIDATE)
- Brand
- DAYTRANA
- Manufacturer
- Noven Pharmaceuticals Inc
- Hazard
- defective-delivery-system
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (14)
- Lot#: 91474
- 91959
- Exp. 3/2023
- 91958
- Exp. 6/2023
- 92478
- Exp. 7/2023
- 92479 & 92198
- Exp. 8/2023
- 92199
- 93040
- Exp. 9/2023
- 93041
- Exp. 10/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DAYTRANA
- HighDaytrana methylphenidate patches recalled for defective delivery system
FDA (Drugs) · 2023-03-29
- HighDaytrana Methylphenidate Patches Recalled for Defective Transdermal Delivery System
FDA (Drugs) · 2023-03-29
- ModerateDaytrana Methylphenidate Patches Recalled for Defective Delivery System
FDA (Drugs) · 2023-03-29
- HighDaytrana transdermal methylphenidate patches recalled for adhesive defect
FDA (Drugs) · 2022-12-07
- HighMethylphenidate Patch Recall: Defective Delivery System and Adhesive Issues
FDA (Drugs) · 2022-07-06
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27